A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk: benefit profile and led to a termination

Conditions

Infections, Bacterial

Interventions

DRUG: GSK1322322 1200 mg
DRUG: GSK1322322 3000 mg
DRUG: Placebo
DRUG: Moxifloxacin

Sponsor

GlaxoSmithKline